Loading...
skip to Main Content

This page offers you with an array of useful resources related to COVID-19 and the liver, including articles, accounts from healthcare professionals, calls for abstracts, and statements.
You are welcome to send suggestions of materials to include to us at marcomms@easloffice.eu

EASL webcasts

EASL has launched a series of webcasts relating to COVID-19. The speakers are world-renowned scientists and clinicians who discuss and share their knowledge about the latest developments of the virus.

Ask EASL podcast

In this upcoming Ask EASL podcast on COVID-19 vaccination, Prof. Markus Cornberg will address and discuss questions from patients associations to Prof. Daniel Shouval and Dr. Christiane Eberhardt.
Coming soon!

EASL-WHO webinar on COVID-19 and the liver

Don’t miss this special webinar on COVID-19 and the liver organised by EASL and the World Health Organization (WHO).

Listen to a panel of leading international experts and clinicians in hepatology and virology presenting the latest information on the COVID-19 pandemic, the WHO response, and how the pandemic is affecting the care of people with liver disease and viral hepatitis, both from a clinical and public health perspective. Then hear from frontline clinicians and programme managers from different countries on their experiences in the COVID-19 national response, and in managing the impact on hepatitis services during the current crisis. Viewers submitted their questions from around the world. You can read the Q&A, with expert answers.

EASL Campus series of webinars on COVID-19 and the liver

Limited knowledge on COVID-19 has evidenced the importance of sharing up-to-date information. Working with world-renowned experts, EASL has launched a series of open-access webinars relating to COVID-19 and the liver. Watch the webinars and stay tuned for more.

1. Virological Aspects of COVID-19
2. Viral markers and the diagnosis of COVID-19
3. Viral testing and the immune response to COVID-19

EASL, ESOT-ELITA and ILTS joint webinar

A joint webinar on the impact of COVID-19 on liver transplantation. ESOT-ELITA, EASL and ILTS speakers discuss the effects of the pandemic on liver transplantation in Europe and in the United States as well as the response of medical societies in regard to education.

Watch the COVID-19 & liver transplantation webinar.

Testimonials on dealing with the public health crisis

EASL Viewpoints are testimonials, interviews, and videos from healthcare professionals sharing life from the frontlines, across Europe.

In their testimonials, hepatologists, liver nurses, researchers, and academics tell how their working life has been affected by COVID-19 and what might be to come.

France, Italy, Portugal, Sweden, the UK… and more to come – watch the videos, read the interviews, and get to meet members of the hepatology community.

Access EASL Viewpoints

News from the EASL supported COVID-Hep registry

Press release, 21/05/2020

A new international study has found increased mortality rates from COVID-19 among people with chronic liver disease and cirrhosis and has called for patients with worsening liver function to be tested for coronavirus.

The researchers, led by teams at Oxford University Hospitals NHS Foundation Trust and the University of North Carolina, set up an international registry (the EASL supported COVID-hep registry, see below) to collect clinical details of patients with chronic liver disease and cirrhosis who develop COVID-19. Between 25 March 2020 and 20 April 2020, 152 cases were submitted to the registry, over 95% of which were hospitalised. Patients with cirrhosis had poor outcomes with an overall death rate of 40 percent. Those with advanced disease called decompensated cirrhosis had the highest rate of death (between 43 and 63 percent), compared with 12 percent for patients with liver disease but without cirrhosis.

Read more.

The EASL supported COVID-Hep registry was launched at the University of Oxford, UK on 23 March 2020. The registry is collecting data on patients, with liver disease at any stage or liver transplants, that have also developed laboratory-confirmed COVID-19. On 21 May, a study based on the first 152 consecutive submissions was published in the Journal of Hepatology.

As of 22 September, data collected (combined with data from SECURE-cirrhosis who are covering the Americas, China, Japan, and Korea) has grown to 1,335 submissions, constituting 1,149 cases and 232 deaths; 545 with cirrhosis
and 170 liver transplant recipients. Browse the weekly updates and downloadable reports.

To find out more or make a submission, visit COVID-Hep. You can also request updates by email.

Read more

Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID Position Paper

EASL-ESCMID Position Paper: a review, six months into the pandemic

Six months into the COVID-19 pandemic, an article has been published in JHEP Reports to provide guidance for physicians involved in the care of patients with chronic liver disease. It serves as an update, summarising the evidence for liver disease involvement during COVID-19 and providing recommendations on how to return to routine care wherever possible.

EASL-ESCMID-covid-statement

In response to the COVID-19 pandemic, EASL and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) have issued a Position Paper providing recommendations for clinicians on caring for patients with liver diseases and for liver transplant recipients. The joint Position Paper also provides a flowchart and an overview of current treatment options, to help clinicians with decision-making during this resource-strapped time.

External resources on COVID-19

BioMed Alliance submits Joint Statement to EU leaders

biomed-alliance-cover

Subsequent to the disruption caused by the COVID-19 pandemic, EASL and 32 other leading European medical associations – together forming the Biomedical Alliance in Europe (BioMed Alliance) – have submitted a joint statement to EU leaders.

Read more 

Latest news from the community

Register for #ILC2021 with early fees & enjoy savings of up to EUR 450!

So how about upgrading your bike? 🚵‍♂️🚴‍♂️🚴 Too much time inside calls for some outdoor exercise.

➡️Register now: https://easl.eu/ILC2021-reg

Tell us below what you’ll do with your early-fee savings.

CHB patients routinely undergo screening for #HCC, but the efficacy of screening is unclear.

@gnioannou, @FengSu_MD & co. reported that screening by ultrasound and/or serum AFP was associated with a reduction in HCC-related mortality.

Read: https://bit.ly/3nZsMjR
#LiverTwitter

New Research | Assessing the impact of #COVID19 on #livercancer management (CERO-19).

Read open access at https://bit.ly/37HnnIj
@ma5RN @massimoiava @Alexfornergon @BCLC_group @policlinicoMI

💻Learn from Dr Julian Schulze-zur-Wiesch about the "Overview of the #COVID19 vaccines available in Europe".

➡️Register for the webinar at no cost: http://bit.ly/EASL-COVID-19

@EASLedu @JHepatology

AISF meeting goes virtually, but AISF remains a REAL place to share ideas and opportunity for increase knowledge on #liver diseases. @AghemoAlessio @salvatore_petta @MarcoMarzioni74 @lucavalenti75 @EASLedu https://twitter.com/AisfFegato/status/1366671885057024002

PNPLA3 associated with reduced #COVID-19 mortality & hospitalisation @AGA_Gastro

✳️Cohorts🇬🇧🇫🇮🇮🇹
✳️rs738409⬆️liver disease⬇️COVID death
✳️Does this help link lipid handling with #SARS-CoV-2 immune response??

👏Hamish Innes, Stephan Buch & Felix Stickel👏
https://bit.ly/3kzOb2z

CHB patients routinely undergo screening for #HCC, but the efficacy of screening is unclear.

@gnioannou, @FengSu_MD & co. reported that screening by ultrasound and/or serum AFP was associated with a reduction in HCC-related mortality.

Read: https://bit.ly/3nZsMjR
#LiverTwitter

New Research | Translatomic profiling reveals novel self-restricting virus-host interactions during #HBV infection.

👉Read at https://bit.ly/3k9Sz81
#livertwitter

Patients with CHB show functional defects of #HBV-specific T cell responses.

@phisquarelab showed that a combination of antioxidants & polyphenols may be a promising strategy for immune reconstitution therapies in CHB.

👉Read open access at https://bit.ly/3724Lla
#livertwitter

Back To Top